Compare
Abeona Therapeutics Inc. vs Puma Biotechnology, Inc. vs Pliant Therapeutics, Inc. vs Evolus, Inc.
| Latest fiscal year | Abeona Therapeutics Inc. ABEORevenue covers only part of its income (partial revenue) | Puma Biotechnology, Inc. PBYI | Pliant Therapeutics, Inc. PLRX | Evolus, Inc. EOLS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $228.37M | $0 | $297.18M |
| Revenue growth (YoY) | n/a | -0.9% | n/a | +11.6% |
| Gross margin | n/a | 74.5% (computed) | n/a | 66.3% |
| Operating margin | n/a | 16.3% | n/a | -11.0% |
| Net margin | n/a | 13.6% | n/a | -17.4% |
| Net income | $71.18M | $31.11M | -$149.34M | -$51.64M |
| EPS (Diluted) | $1.01 | $0.61 | -$2.43 | -$0.80 |
| Operating cash flow | -$76.33M | $41.80M | -$128.34M | -$42.27M |
| Free cash flow | -$84.30M | $41.73M | -$128.71M | -$45.71M |
| Cash & equivalents | $78.44M | $29.64M | $45.45M | $53.83M |
| Total assets | $219.57M | $216.30M | $225.23M | $225.87M |
| Total liabilities | $60.35M | $85.96M | $44.02M | $248.97M |
| Shareholders' equity | $159.22M | $130.34M | $181.21M | -$23.11M |
| Return on year-end equity | 44.7% | 23.9% | -82.4% | n/a |
| Shares outstanding | 55.04M | 50.41M | 61.45M | 65.01M |
Revenue, most recent five fiscal years
| Fiscal year | Abeona Therapeutics Inc. | Puma Biotechnology, Inc. | Pliant Therapeutics, Inc. | Evolus, Inc. |
|---|---|---|---|---|
| Latest | n/a | $228.37M Ended 2025-12-31 | $0 Ended 2025-12-31 | $297.18M Ended 2025-12-31 |
| 1 year earlier | n/a | $230.47M Ended 2024-12-31 | $0 Ended 2024-12-31 | $266.27M Ended 2024-12-31 |
| 2 years earlier | n/a | $235.64M Ended 2023-12-31 | $1.58M Ended 2023-12-31 | $202.09M Ended 2023-12-31 |
| 3 years earlier | n/a | $228.03M Ended 2022-12-31 | $9.69M Ended 2022-12-31 | $148.62M Ended 2022-12-31 |
| 4 years earlier | n/a | $253.16M Ended 2021-12-31 | $7.57M Ended 2021-12-31 | $99.67M Ended 2021-12-31 |